The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models

American Journal of Transplantation

Volumn 4, Issue 1, 2004, Pages 51-57

  Kudlacz, Elizabeth ^a   Perry, Bret ^a   Sawyer, Perry ^a   Conklyn, Maryrose ^a   McCurdy, Sandra ^a   Brissette, William ^a   Flanagan, Mark ^a   Changelian, Paul ^a  

^a PFIZER INC   (United States)

Author keywords

Immunosuppression; JAK 3 inhibitor; Murine models

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 4 METHYL 3 (METHYL 1H PYRROLO[2,3 D]PYRIMIDIN 4 YLAMINO) BETA OXO 1 PIPERIDINE PROPANENITRILE; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE; JANUS KINASE 3; PHOSPHOTRANSFERASE INHIBITOR; PYRROLIDINE DERIVATIVE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EXTERNAL EAR; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HOMEOSTASIS; IC 50; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIXED LYMPHOCYTE REACTION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TIME;

ANIMALS; CELL SEPARATION; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; INHIBITORY CONCENTRATION 50; JANUS KINASE 3; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE SUBSETS; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; PROTEIN-TYROSINE KINASES; SPLEEN; THYMUS GLAND; TIME FACTORS; TRANSPLANTATION;

EID: 0742318929     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6143.2003.00281.x     Document Type: Article

References (42)

1. Leonard WJ, Lin J-X. Cytokine receptor signaling pathways. J Allergy Clin Immunol 2000; 105: 877-888.
2. Notarangelo LD, Giliani S, Mazza C et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the γ c-JAK3 signaling pathway as a model. Immunol Rev 2000; 178: 39-48.
3. Thomis DC, Berg LJ. The role of Jak3 in lymphoid development, activation, and signaling. Curr Opin Immunol 1997; 9: 541-547.
4. Suzuki K, Nakajima H, Saito Y, Saito T, Leonard WJ, Iwamoto I. Janus kinase 3 (Jak3) is essential for common cytokine receptor γ chain (γ c) -dependent signaling: comparative analysis of γ c, Jak3, and γ c and Jak3 double-deficient mice. Int Immunol 2000; 12: 123-132.
5. Enyon EE, Kuida K, Flavell RA. Disruption of cytokine signaling in lymphoid development: unique contributions of the common cytokine gamma chain and the Jak3 kinase. J Interferon Cytokine Res 1996; 16: 677-684.
6. Perico N, Remuzzi G. Prevention of transplant rejection. Current treatment guidelines and future developments. Drugs 1997; 54: 533-570.
7. Kirken RA. Targeting JAK3 for immune suppression and allograft acceptance. Transplant Proc 2001; 33: 3268-3270.
8. Changelian P, Kent C, Magnuson K et al. Development of a JAK3 inhibitor to prevent organ allograft rejection. Am J Transplant 2003; 3 (Suppl. 5): abstract # 596.
9. Di Pierro F, d'Atri G, Marcucci F, Leoni F. Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs. J Pharm Toxicol Meth 1997; 37: 91-96.
10. Roudebush RE, Bryant HU. Pharmacologic manipulation of a four day murine delayed type hypersensitivity model. Agents Actions 1993; 38: 116-121.
11. Nosaka T, van Deursen JM, Tripp RA et al. Defective lymphoid development in mice lacking Jak3. Science 1995; 270: 800-802.
12. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995; 270: 794-797.
13. Park SY, Saijo K, Takahashi T et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995; 3: 771-782.
14. Cao X, Shores EW, Hu-Li J et al. Defective lymphoid development in mice lacking expression of the common receptor γ chain. Immunity 1995; 2: 223-238.
15. Lodolce JP, Boone DL, Chai S et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9: 669-676.
16. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771-780.
17. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in IL-7 gene deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181: 1519-1526.
18. Peschon JJ, Morrissey PJ, Grabstein KH et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994; 180: 1955-1960.
19. Bhatia SK, Tygrett LT, Grabstein KH, Waldschmidt TJ. The effect of in vivo IL-7 deprivation on T cell maturation. J Exp Med 1995; 181: 1399-1409.
20. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991; 352: 621-624.
21. Kasaian MT, Whitters MJ, Carter LL et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002; 16: 559-569.
22. Reddy MP, Webb EF, Cassatt D et al. Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses. Int J Immunopharm 1994; 16: 795-804.
23. Sehgal SN. Rapamune® (RAPA, rapamycin, sirolimus). Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340.
24. Klupp J, Langrehr JM, Junge G, Neuhaus P. Inhibitors of mammalian target of rapamycin. Drugs Future 2001; 26: 1179-1189.
25. Jordan WJ, Ritter MA. Optimal analysis of composite cytokine responses during alloreactivity. J Immunol Meth 2002; 260: 1-14.
26. Fulmer RI, Cramer AT, Liebelt RA, Liebelt AG. Transplantation of cardiac tissue into the mouse ear. Am J Anat 1963; 113: 273-286.
27. Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK 506 and rapamycin on the suppression of allograft rejection. Transplant Proc 1990; 22: 1638-1641.
28. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659-1662.
29. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule-dependence, tolerance induction, synergy with cyclosporine and FK506 and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991; 23: 521-524.
30. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med 1991; 174: 493-496.
31. Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002; 73: 1808-1817.
32. Manfro RC, Roy-Chaudhury P, Zheng XX et al. Interleukin-15 gene transcripts are present in rejecting islet allografts. Transplant Proc 1997; 29: 1077-1078.
33. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995; 155: 489-498.
34. Van Gelder T, Baan CC, Balk AH et al. Blockade of the interleukin (IL) -2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation 1998; 65: 405-410.
35. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
36. Kim YS, Maslinski W, Zheng XX et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ; 2a protein blocks delayed-type hypersensitivity. J Immunol 1998; 160: 5742-5748.
37. Smith XG, Bolton EM, Ruchatz H, Wei X-Q, Liew FY, Bradley JA. Selective blockade of IL-15 by soluble IL-15 receptor α-chain enhances cardiac allograft survival. J Immunol 2000; 165: 3444-3450.
38. Ferrari-Lacraz S, Zheng XX, Kim YS et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001; 167: 3478-3485.
39. Behbod F, Erwin-Cohen RA, Wang ME et al. Concomitant inhibition of janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 2001; 166: 3724-3742.
40. Stepkowski SM, Erwin-Cohen RA, Behbod F et al. Selective inhibitor of janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002; 99: 680-689.
41. Cetkovic-Cvrlje M, Roers BA, Waurzyniak B, Liu X-P, Uckun FM. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001; 98: 1607-1613.
42. Borie D, Larson M, Changelian P et al. Targeted inhibition of JAK3 with CP-690,550 significantly prolongs allograft survival in a non-human primate model of renal transplantation. Am J Transplant 2003; 3 (Suppl. 5): abstract #4.